PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab’)2
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043387 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mengyuan Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Jilin University, Changchun 130062, China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research and Development of COVID-19 Vaccine for Animals, Ministry of Science and Technology of the People’s Republic of China.
Abstract (Originalsprache)
Therapeutic antibodies-F(ab’)2 obtained from hyperimmune equine plasma could treat emerging infectious diseases rapidly because of their high neutralization activity and high output. However, the small-sized F(ab’)2 is rapidly eliminated by blood circulation. This study explored PEGylation strategies to maximize the half-life of equine anti-SARS-CoV-2 specific F(ab’)2. Equine anti-SARS-CoV-2 specific F(ab’)2 were combined with 10 KDa MAL-PEG-MAL in optimum conditions. Specifically, there were two strategies: Fab-PEG and Fab-PEG-Fab, F(ab’)2 bind to a PEG or two PEG, respectively. A single ion exchange chromatography step accomplished the purification of the products. Finally, the affinity and neutralizing activity was evaluated by ELISA and pseudovirus neutralization assay, and ELISA detected the pharmacokinetic parameters. The results displayed that equine anti-SARS-CoV-2 specific F(ab’)2 has high specificity. Furthermore, PEGylation F(ab’)2-Fab-PEG-Fab had a longer half-life than specific F(ab’)2. The serum half-life of Fab-PEG-Fab, Fab-PEG, and specific F(ab’)2 were 71.41 h, 26.73 h, and 38.32 h, respectively. The half-life of Fab-PEG-Fab was approximately two times as long as the specific F(ab’)2. Thus far, PEGylated F(ab’)2 has been prepared with high safety, high specificity, and a longer half-life, which could be used as a potential treatment for COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Jilin University, Changchun 130062, China.
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130012, China.
- Center of Infectious Disease Research, Westlake University, Hangzhou 310024, China.
- College of Wildlife and Protected Area, Northeast Forestry University, Harbin 150040, China.
- College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China.
ORCID-Profile: Jinhao Bi
Förderung
- Research and Development of COVID-19 Vaccine for Animals
- Ministry of Science and Technology of the People’s Republic of China
Zitieren
APA
Xu, M., Bi, J., Liang, B., Wang, X., Mo, R., Feng, N., Yan, F., Wang, T., Yang, S., Zhao, Y., & Xia, X. (2023). PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab’)2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043387
Vancouver
Xu M, Bi J, Liang B, Wang X, Mo R, Feng N, et al. PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab’)2. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043387
BibTeX
@article{Xu2023,
author = {Xu, Mengyuan and Bi, Jinhao and Liang, Bo and Wang, Xinyue and Mo, Ruo and Feng, Na and Yan, Feihu and Wang, Tiecheng and Yang, Songtao and Zhao, Yongkun and Xia, Xianzhu},
title = {PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab’)2},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043387}
}
EUVIMED